| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg | |||
| Other Sizes |
| Targets |
IRAK-1/4 Inhibitor targets interleukin-1 receptor-associated kinase 1 (IRAK-1) and IRAK-4. It has IC50 values of 0.3 µM for IRAK-1 and 0.2 µM for IRAK-4. The compound displays IC50 values >10 µM in a panel of 27 other kinases tested, indicating good selectivity for IRAK-1 and IRAK-4. By inhibiting these kinases, it blocks downstream signaling pathways that lead to the production of pro-inflammatory cytokines.
|
|---|---|
| ln Vitro |
The IC50 of IRAK-1-4 Inhibitor I was the highest concentration tested (10 μM) against 27 additional clades, including the closest homologous (IRAK family independent) Lck and pp60SRC. Furthermore, IRAK-1-4 Inhibitor I did not demonstrate any significant cytotoxicity (ED50>30 μM) in a 72 h proliferation assay in HeLa cells. IRAK-1-4 Inhibitor I (IRAK-1 IC50=0.3 μM) strongly suppresses IRAK-1[1] IRAK-1-4 Inhibitor I can remove the LPS-induced increases in Bcl10, NF-κB and IL-8. IRAK-1-4 Inhibitor I mediates LPS-induced IL-8 activation and operates upstream of Bcl10. The LPS-induced increase in Bcl10 dropped by 73% (from 5.18±0.22 to 2.36±0.08 ng/mL), and the IL-8 response recovered by 60% (from 2.64±0.31 to 1.14±0.08 ng/mL) [2].
IRAK-1/4 Inhibitor demonstrates potent inhibitory activity against IRAK-1 and IRAK-4 with IC50 values of 0.3 µM and 0.2 µM, respectively. It mediates LPS-induced IL-8 activation. The LPS-induced increase in Bcl10 dropped by 73% (from 5.18±0.22 to 2.36±0.08 ng/mL), and the IL-8 response recovered by 60% (from 2.64±0.31 to 1.14±0.08 ng/mL) in the presence of the inhibitor. |
| ln Vivo |
In vivo activity data for IRAK-1/4 Inhibitor is not detailed in the provided references. However, given its potent in vitro activity against IRAK-1 and IRAK-4 and its role in modulating TLR/IL-1R signaling, the compound is expected to be effective in animal models of inflammatory and autoimmune diseases. Its high potency and specificity make it suitable for in vivo applications.
|
| Enzyme Assay |
The primary in vitro assay for IRAK-1/4 Inhibitor is a kinase activity assay using purified recombinant IRAK-1 and IRAK-4 enzymes. The assay measures the compound's ability to inhibit the phosphorylation of a substrate by the kinases, and the IC50 values are determined from dose-response curves. This cell-free system allows for the direct assessment of the compound's inhibitory potency against the target enzymes.
|
| Cell Assay |
In vitro cellular assays for IRAK-1/4 Inhibitor involve treating cells with the compound and measuring its effect on downstream signaling pathways. For example, the compound's ability to inhibit LPS-induced IL-8 activation can be assessed by measuring IL-8 levels in cell culture supernatants by ELISA. Its effect on Bcl10 levels can also be measured by Western blot or ELISA. These assays confirm the compound's activity in a cellular context.
|
| Animal Protocol |
In vivo animal experiments for IRAK-1/4 Inhibitor are not detailed in the provided references. However, as an inhibitor of the TLR/IL-1R signaling pathway, it could be evaluated in animal models of sepsis, inflammatory bowel disease, or autoimmune diseases such as rheumatoid arthritis. The compound's efficacy in reducing inflammation and disease severity would be assessed in such models.
|
| ADME/Pharmacokinetics |
IRAK-1/4 Inhibitor has a molecular weight of 395.41 and a molecular formula of C20H21N5O4. It is soluble in DMSO, with a solubility of 8 mg/mL (20.23 mM). The compound is typically used in in vitro and in vivo research applications. Its pharmacokinetic properties, such as oral bioavailability and half-life, are not specified in the provided sources.
|
| Toxicity/Toxicokinetics |
Toxicological data for IRAK-1/4 Inhibitor is not detailed in the provided sources. As a research compound, it is not intended for human use and is supplied for laboratory research purposes only. Standard safety precautions should be followed when handling this compound. Its safety profile would need to be established through preclinical studies for therapeutic development.
|
| References |
|
| Additional Infomation |
IRAK-1/4 Inhibitor is a potent and selective inhibitor of IRAK-1 and IRAK-4 with IC50 values of 0.3 µM and 0.2 µM, respectively. It displays excellent selectivity over 27 other kinases tested. This compound is widely used in immunology research to study inflammatory and autoimmune diseases by targeting the TLR/IL-1R signaling pathway. It mediates LPS-induced IL-8 activation and operates upstream of Bcl10. It is available for research purposes from various chemical suppliers.
|
| Molecular Formula |
C20H21N5O4
|
|---|---|
| Molecular Weight |
395.41184
|
| Exact Mass |
395.159
|
| CAS # |
509093-47-4
|
| Related CAS # |
509093-47-4;
|
| PubChem CID |
11983295
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.4
|
| LogP |
3.374
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
29
|
| Complexity |
580
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
QTCFYQHZJIIHBS-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C20H21N5O4/c26-19(15-4-3-5-16(14-15)25(27)28)22-20-21-17-6-1-2-7-18(17)24(20)9-8-23-10-12-29-13-11-23/h1-7,14H,8-13H2,(H,21,22,26)
|
| Chemical Name |
N-[1-(2-morpholin-4-ylethyl)benzimidazol-2-yl]-3-nitrobenzamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMF : 25 mg/mL (~63.23 mM)
DMSO : ~5 mg/mL (~12.65 mM) H2O : < 0.1 mg/mL Ethanol :< 1 mg/mL |
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5290 mL | 12.6451 mL | 25.2902 mL | |
| 5 mM | 0.5058 mL | 2.5290 mL | 5.0580 mL | |
| 10 mM | 0.2529 mL | 1.2645 mL | 2.5290 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
